Pfizer/BioNTech pause post‑market study
What happened
Pfizer and BioNTech paused a large U.S. post‑marketing COVID‑vaccine study in healthy 50–64‑year‑olds because enrolment was too low to meet the FDA's evidence requirements. The pause shows that post‑authorisation studies remain enforceable obligations and may need contingency plans if feasibility or uptake undermines timely completion. (pharmexec.com)
Why it matters
Pfizer and BioNTech had planned a very large U.S. study and set an enrollment target of roughly 25,000–30,000 healthy adults aged 50–64, but they closed recruitment on March 6 and informed study investigators in a March 30 letter that routine surveillance of participants would stop after April 3. (reuters.com) The companies said the decision was not driven by safety or benefit‑risk concerns and that they notified the U.S. drug regulator of their intent to halt the study. (reuters.com) The pause affects a post‑authorization commitment — a study required after a vaccine is authorized to produce additional evidence — and the U.S. regulator had specifically asked for a large, placebo‑controlled trial in the 50–64 age group; a placebo‑controlled trial is one in which some participants receive an inactive pill or injection so investigators can compare outcomes against those who received the vaccine. (reuters.com) Recruitment proved unusually difficult because the trial’s eligibility required participants to be free of common chronic conditions (for example, no hypertension or diabetes), a threshold that one contract research organization executive told reporters led more than 80% of willing volunteers to fail pre‑screening; that screening difficulty contributed to the enrollment shortfall. (pharmexec.com) The companies framed the move as a feasibility decision rather than a safety signal, but regulators’ insistence on randomized, placebo‑controlled data for that age band — and the fact that no COVID‑19 vaccines have since been approved for routine use in 50–64‑year‑olds under the tightened requirements — means the halted study removes a primary pathway for expanding official vaccine recommendations for that group. (reuters.com) Industry observers and the companies noted the outcome highlights that post‑authorization studies remain enforceable obligations and that sponsors may need predefined contingency plans (for example, alternate study designs or real‑world evidence strategies) if trial feasibility or low public uptake prevents timely completion. (pharmexec.com)
Key numbers
- post‑marketing COVID‑vaccine study in healthy 50–64‑year‑olds because enrolment was too low to meet the FDA's evidence requirements.
- study and set an enrollment target of roughly 25,000–30,000 healthy adults aged 50–64, but they closed recruitment on March 6 and informed study investigators in a March 30 letter that routine surveillance of participants would stop after April 3.
What happens next
- study and set an enrollment target of roughly 25,000–30,000 healthy adults aged 50–64, but they closed recruitment on March 6 and informed study investigators in a March 30 letter that routine surveillance of participants would stop after April 3.
- The pause shows that post‑authorisation studies remain enforceable obligations and may need contingency plans if feasibility or uptake undermines timely completion.
Quick answers
What happened in Pfizer/BioNTech pause post‑market study?
Pfizer and BioNTech paused a large U.S. post‑marketing COVID‑vaccine study in healthy 50–64‑year‑olds because enrolment was too low to meet the FDA's evidence requirements. The pause shows that post‑authorisation studies remain enforceable obligations and may need contingency plans if feasibility or uptake undermines timely completion. (pharmexec.com)
Why does Pfizer/BioNTech pause post‑market study matter?
Pfizer and BioNTech had planned a very large U.S. study and set an enrollment target of roughly 25,000–30,000 healthy adults aged 50–64, but they closed recruitment on March 6 and informed study investigators in a March 30 letter that routine surveillance of participants would stop after April 3. (reuters.com) The companies said the decision was not driven by safety or benefit‑risk concerns and that they notified the U.S. drug regulator of their intent to halt the study. (reuters.com) The pause affects a post‑authorization commitment — a study required after a vaccine is authorized to produce additional evidence — and the U.S. regulator had specifically asked for a large, placebo‑controlled trial in the 50–64 age group; a placebo‑controlled trial is one in which some participants receive an inactive pill or injection so investigators can compare outcomes against those who received the vaccine. (reuters.com) Recruitment proved unusually difficult because the trial’s eligibility required participants to be free of common chronic conditions (for example, no hypertension or diabetes), a threshold that one contract research organization executive told reporters led more than 80% of willing volunteers to fail pre‑screening; that screening difficulty contributed to the enrollment shortfall. (pharmexec.com) The companies framed the move as a feasibility decision rather than a safety signal, but regulators’ insistence on randomized, placebo‑controlled data for that age band — and the fact that no COVID‑19 vaccines have since been approved for routine use in 50–64‑year‑olds under the tightened requirements — means the halted study removes a primary pathway for expanding official vaccine recommendations for that group. (reuters.com) Industry observers and the companies noted the outcome highlights that post‑authorization studies remain enforceable obligations and that sponsors may need predefined contingency plans (for example, alternate study designs or real‑world evidence strategies) if trial feasibility or low public uptake prevents timely completion. (pharmexec.com)
